Alzheimer's Drugs Market Report 2025

The alzheimer's drugs market size has grown strongly in recent years. It will grow from $9.33 billion in 2024 to $10.19 billion in 2025 at a compound annual growth rate (CAGR) of 9.1%. The growth in the historic period can be attributed to rise in Alzheimer’s disease cases, investments in research and development, improved understanding of disease mechanisms, global health initiatives, public awareness and education.

The alzheimer's drugs market size is expected to see strong growth in the next few years. It will grow to $14.47 billion in 2029 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to precision medicine approaches, focus on disease modification, biomarker identification and validation, patient-centric drug development, focus on non-pharmacological interventions. Major trends in the forecast period include diverse therapeutic approaches, digital health solutions, regenerative medicine, advancements in diagnostic technologies, artificial intelligence (AI) in drug discovery, partnerships and collaborations.

The increasing prevalence of Alzheimer's disease is anticipated to drive the growth of the Alzheimer's drugs market in the coming years. Alzheimer's disease is a progressive neurological condition that leads to brain shrinkage and cell death over time. Medications for Alzheimer's are designed to address memory loss, cognitive impairments, and challenges in daily living. These drugs can improve the quality of life and help individuals maintain their independence. For example, in May 2024, a report from the Alzheimer’s Association, a US-based nonprofit focused on Alzheimer's care, support, and research, indicated that the number of Americans aged 65 and older diagnosed with Alzheimer's dementia increased from 6.5 million in 2022 to an estimated 6.9 million in 2024.

The rising healthcare funding is projected to drive the growth of the Alzheimer’s drugs market in the coming years. Increased funding in healthcare facilitates extensive research and development, supports clinical trials, enables advanced diagnostic technologies, and provides access to specialized healthcare services. It also implements awareness programs and develops necessary infrastructure. Furthermore, this funding plays a crucial role in enhancing patient access to medications and addressing the challenges related to Alzheimer's disease, fostering innovation in both drug development and patient care. For instance, in May 2023, a report from the Office for National Statistics, a UK-based government department, indicated that healthcare spending in the UK rose by 5.6% from 2022 to 2023, compared to a growth rate of 0.9% in 2022. The total healthcare expenditure in the UK was approximately $317.63 billion (£292 billion) in 2023.

Key players in the Alzheimer’s drugs market are focusing on developing innovative treatments, such as amyloid plaque-targeting therapy, to enhance treatment options and improve patient outcomes. This therapy specifically targets the reduction or prevention of amyloid-beta plaque accumulation in the brain, which is associated with Alzheimer’s disease. For instance, in June 2024, Eli Lilly and Company, a US-based pharmaceutical firm, received approval from the Food and Drug Administration (FDA) for Kisunla (donanemab-azbt). Kisunla is notable as the first and only amyloid plaque-targeting therapy designed for early symptomatic Alzheimer's disease. It functions by assisting the body in removing excess amyloid plaques from the brain, which are linked to cognitive decline in Alzheimer's patients. Kisunla is administered via intravenous infusion every four weeks, with an initial dosing regimen of 700 mg for the first three doses, followed by 1400 mg thereafter. It is specifically indicated for adults experiencing mild cognitive impairment (MCI) and mild dementia stages of Alzheimer's disease, contingent upon confirmed amyloid pathology.

Major companies operating in the alzheimer’s drugs market are developing new combination therapies to sustain their position in the market. Combination therapies refer to the simultaneous use of two or more therapeutic agents or treatment modalities to address a medical condition. For instance, in April 2022, NovaMedica LLC, a Russia-based pharmaceutical company launched an innovative Alzheimer's disease therapy named MYOREOL. The drug, developed and registered by NovaMedica, is a combination of donepezil and memantine molecules, marking the first of its kind in Russia, the EAEU, and Europe. MYOREOL aims to enhance treatment retention and effectiveness in patients with moderate and severe dementia associated with Alzheimer's disease.

In March 2022, AbbVie, a US-based publicly traded biopharmaceutical company, acquired Syndesi Therapeutics for an undisclosed amount. This acquisition grants AbbVie access to Syndesi's portfolio of new modulators of the synaptic vesicle protein 2A (SV2A), including its lead compound SDI-118, and will aid in the expansion of AbbVie's neuroscience product line. Syndesis Therapeutics is a Belgium-based company that treats Alzheimer’s disease and other disorders with cognitive impairment.

Major companies operating in the alzheimer's drugs market include AbbVie Inc., Daiichi Sankyo Company Limited, F Hoffmann-La Roche AG, Merck & Co Inc., Novartis AG, Biogen Inc., AstraZeneca PLC, Eisai Co Ltd., Eli Lilly and Company, H Lundbeck A/S, Pfizer Inc., Allergan PLC., Johnson & Johnson, Lupin Pharmaceuticals Inc., Actiza Pharmaceutical Private Limited, Neurotrope Inc., AC Immune SA, Adamas Pharmaceuticals Inc, Alzheon Inc., Anavex Life Sciences Corp, Axsome Therapeutics Inc., Cassava Sciences Inc., Cognition Therapeutics Inc., Cortexyme Inc., Denali Therapeutics Inc, EIP Pharma Inc., Enlivex Therapeutics Ltd., FORUM Pharmaceuticals Inc., Genentech Inc., Green Valley Pharmaceuticals LLC, Intra-Cellular Therapies Inc., Karuna Therapeutics Inc., Neurim Pharmaceuticals Ltd.

North Americawas the largest region in the Alzheimer's drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the Alzheimer’s drugs market during the forecast period. The regions covered in the alzheimer's drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the alzheimer's drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Alzheimer's drugs are medications designed to assist in the management of symptoms related to memory loss, cognitive issues, and daily functioning challenges associated with Alzheimer's disease - a progressive brain disorder characterized by a gradual decline in memory, reasoning, and learning abilities.

The primary drugs used for Alzheimer's treatment include donepezil, rivastigmine, galantamine, and memantine. Donepezil belongs to the class of drugs known as cholinesterase inhibitors. These medications are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies. They find application in treating different stages of Alzheimer's disease, ranging from the early to moderate stages to the moderate to severe stages.

The Alzheimer's drugs market research report is one of a series of new reports that provides Alzheimer's drugs market statistics, including Alzheimer's drugs industry global market size, regional shares, competitors with a Alzheimer's drugs market share, detailed Alzheimer's drugs market segments, market trends and opportunities, and any further data you may need to thrive in the Alzheimer's drugs industry. This Alzheimer's drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The Alzheimer's drugs market consists of sales of cholinesterase inhibitors such as aricept, exelon, and razadyne. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.